

Overview


Horizon R&D thinks creatively, exploring novel approaches in our pursuit of new therapies that fill unmet needs. We are a global team of more than 200 discovery scientists, clinical researchers, operations and technical experts who share a vision to compassionately explore potential new medicines for patients with rare, autoimmune and severe inflammatory diseases.

Our philosophy is to follow what the data tell us. We evaluate avenues to maximize each molecule's scientific potential and the profound impact it could have on a patient's life. This has resulted in a curated pipeline of targeted experimental medicines and novel mechanisms of action.

Highlights



Areas of Focus



¹ Miyamoto BE, Kakkis ED. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. *Orphanet Journal of Rare Diseases*. 2011;6(1):49. doi:10.1186/1750-1172-6-49.

A Pipeline Built with Purpose

Program	Potential Indication	Preclinical	Phase 1	Phase 2	Phase 3
UPLIZNA	IgG4-Related Disease	[Progress bar]			
	Myasthenia Gravis	[Progress bar]			
HZN-825	Diffuse Cutaneous Systemic Sclerosis	[Progress bar]			
	Idiopathic Pulmonary Fibrosis	[Progress bar]			
Dazodalibep (HZN-4920)	Focal Segmental Glomerulosclerosis	[Progress bar]			
	Kidney Transplant Rejection	[Progress bar]			
	Rheumatoid Arthritis	[Progress bar]			
	Sjögren's Syndrome	[Progress bar]			
Daxdilimab (HZN-7734)	Alopecia Areata	[Progress bar]			
	Dermatomyositis	[Progress bar]			
	Discoid Lupus Erythematosus	[Progress bar]			
	Lupus Nephritis	[Progress bar]			
	Systemic Lupus Erythematosus	[Progress bar]			
TEPEZZA	Chronic TED in Japan (OPTIC-J)	[Progress bar]			
	Diffuse Cutaneous Systemic Sclerosis	[Progress bar]			
	Subcutaneous Administration	[Progress bar]			
HZN-1116	Autoimmune Diseases	[Progress bar]			
Alpine	Autoimmune Diseases	[Progress bar]			
Arrowhead	Next-Gen Uncontrolled Gout	[Progress bar]			
HemoShear	Novel Gout Targets	[Progress bar]			

Horizon is exploring the potential of its on-market medicines to identify paths for new treatment methods and improve patient outcomes.

- Quantifying the impact of **TEPEZZA** for patients with **chronic Thyroid Eye Disease**
- Evaluating efficacy and safety of **KRYSTEXXA** in broader patient populations with retreatment (**ADVANCE**)
- Exploring the patient experience with **KRYSTEXXA** – monthly dosing (**FORWARD**) and shorter infusion durations (**AGILE**)

Our Team

Horizon R&D is an agile group of experienced scientists, clinical researchers and technical experts who work with commercial and other functions from the outset of the development process. We unite our expertise to understand the science behind our molecules and the possibilities of therapeutic impact, resulting in creative, cohesive paths for scientific execution.

>70%

Percentage of women on our R&D team

4x

Quadrupled the number of employees on our R&D team since 2018



Partnerships and Growth



Our partnership with Arrowhead Pharmaceuticals is a global collaboration and license agreement for ARO-XDH, a discovery-stage investigational RNA interference (RNAi) therapeutic as a potential treatment for people with uncontrolled gout.



Our partnership with HemoShear, a company with a modeling platform that enables accelerated discovery of novel targets, aims to discover new treatments for gout.



CSR PARTNERSHIPS

We partner with over 14 organizations to advance STEAM education in the communities we serve.



ACADEMIC PARTNERSHIPS

We partner with several academic institutions to pursue research studies for treatments in rare, autoimmune and severe inflammatory diseases.

Locations

Ireland



Our corporate, manufacturing and technical operations headquarters are in **Dublin**. Our manufacturing facility in **Waterford** includes an aseptic filling line and lyophiliser, or freeze dryer, that can be used for our development and commercial medicines.

California



Our facility in **South San Francisco** is a 20,000 square foot R&D hub with laboratory space that will enable formulation and process development for manufacturing, as well as bioanalytical method development.

Illinois



Our U.S. headquarters is in **Deerfield**.

Maryland



Our state-of-the-art laboratory facilities in **Gaithersburg** and **Rockville** provide our teams with resources to evaluate and develop new medicines.